NCT06626737View on ClinicalTrials.gov

Dapagliflozin in Allo-HCT for aGVHD

PHASE2RecruitingINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

April 26, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Graft-versus-host Disease (GVHD)
Interventions
DRUG

Dapagliflozin (DAPA)

Participants will take Dapagliflozin 10mg every day in -1 to 14 days

Trial Locations (1)

215000

RECRUITING

The First Affiliated Hospital of Soochow University, Suzhou

All Listed Sponsors
lead

The First Affiliated Hospital of Soochow University

OTHER